Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Host Immunity and Vaccines for Respiratory Pathogens
share announcement

Host Immunity and Vaccines for Respiratory Pathogens

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 31 January 2026 | Viewed by 1263

Special Issue Editors

Dr. Hanqing He

E-Mail Website
Guest Editor
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
Interests: human vaccines; human immunity; epidemiology and health statistics; health economics
Dr. Yuxia Liang

E-Mail
Guest Editor
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
Interests: human vaccines; infectious disease modelling; epidemiology and health statistics; social contact; human mobility

Special Issue Information

Dear Colleagues,

We invite researchers to contribute to an upcoming Special Issue of Vaccines focusing on “Host Immunity and Vaccines for Respiratory Pathogens”. Respiratory infections, including influenza, RSV, SARS-CoV-2, and emerging pathogens, remain a global health challenge. This Special Issue aims to explore advances in understanding host–pathogen interactions, immune evasion mechanisms, and innovations in vaccine design, evaluation, and deployment.

We welcome original research articles, reviews, and clinical studies addressing topics such as the following: 

  • Innate/adaptive immune responses to respiratory pathogens;
  • Novel vaccine platforms (mRNA, viral vectors, etc.) and adjuvants;
  • Correlates of protection and vaccine efficacy in diverse populations;
  • Mucosal immunity and respiratory tract-targeted strategies;
  • Challenges in vaccine equity and pandemic preparedness;
  • Real world effectiveness of human vaccines.

Submissions will undergo rigorous peer review, and selected papers will highlight cutting-edge science with translational impact. By sharing your insights, you will contribute to shaping future vaccine strategies against respiratory diseases.

We encourage early submissions to ensure timely consideration. Join us in advancing knowledge to combat respiratory pathogens and safeguard global health. 

Dr. Hanqing He
Dr. Yuxia Liang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccines
  • immunity
  • infectious disease
  • respiratory pathogens

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 578 KB  
Article
IgG Antibodies to Pneumococcal Serotypes 1 and 5 in Relation to PCV13 Vaccination Status in Children Aged Under 5 Years in Lao PDR: A Cross-Sectional Survey
by Zheng Quan Toh, Ke Xin Tang, Keoudomphone Vilivong, Jana Lai, Toukta Bounkhoun, Valin Chanthaluanglath, Anisone Chanthongthip, Anne Balloch, Paul N. Newton, Audrey Dubot-Pérès, David A. B. Dance, Paul V. Licciardi and Fiona M. Russell
Vaccines 2025, 13(8), 873; https://doi.org/10.3390/vaccines13080873 - 18 Aug 2025
Viewed by 342
Abstract
Background/Objectives: Pneumococcal serotypes 1 and 5 are associated with invasive pneumococcal disease (IPD). However, data on the circulation of these serotypes in Asia following the introduction of the pneumococcal conjugate vaccine (PCV) is limited. The Lao People’s Democratic Republic (Lao PDR) introduced PCV13 [...] Read more.
Background/Objectives: Pneumococcal serotypes 1 and 5 are associated with invasive pneumococcal disease (IPD). However, data on the circulation of these serotypes in Asia following the introduction of the pneumococcal conjugate vaccine (PCV) is limited. The Lao People’s Democratic Republic (Lao PDR) introduced PCV13 into its national immunisation programme in 2013. We undertook a serosurvey to assess the IgG responses to serotypes 1 and 5 from a convenience sample of children aged under 5 years in Vientiane, Lao PDR. Methods: This cross-sectional analysis used a convenience sample of the close contacts of children under five years old who had been hospitalised with acute respiratory infections between 2013 and 2016 in Vientiane, Lao PDR. Serotype-specific IgG concentrations to serotypes 1 and 5 were measured using a modified WHO ELISA method. Results: A total of 214 participants were included, 130 of whom were unvaccinated and 84 were vaccinated with PCV13. Compared to unvaccinated participants, a higher number of PCV-vaccinated participants met the IgG threshold for IPD (≥0.35 μg/mL) [41.5% (54/130) vs. 71.4% (60/84)] for serotype 1. In contrast, for serotype 5, a similar number of participants in the PCV-vaccinated and unvaccinated group met the IgG threshold for IPD (85.7% (72/84) vs. 82.3% (107/130). Among unvaccinated children, serotype 1 IgG levels peaked at 12 and 23 months at 0.49 µg/mL (95% CIs: 0.25–0.96), while serotype 5 IgG levels were similar across age groups, ranging from 0.55 to 0.79 µg/mL. Conclusions: Our findings indicate the considerable circulation of serotypes 1 and 5 within the community in Lao PDR. Ongoing surveillance is important for informing PCV vaccination strategies. Full article
(This article belongs to the Special Issue Host Immunity and Vaccines for Respiratory Pathogens)
►▼ Show Figures

Figure 1

16 pages, 1414 KB  
Article
Integrated Analysis of the Safety Experience in Adults with the Bivalent Respiratory Syncytial Virus Prefusion F Vaccine
by Kumar Ilangovan, David Radley, Michael Patton, Emma Shittu, Maria Maddalena Lino, Christos Goulas, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman and Iona Munjal
Vaccines 2025, 13(8), 827; https://doi.org/10.3390/vaccines13080827 - 1 Aug 2025
Viewed by 571
Abstract
Background/objectives: This was a post hoc analysis of safety data across the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine clinical trial development program. Methods: Data from eight clinical trials in 46,913 immunocompetent adults who received RSVpreF or placebo were analyzed. Local reactions [...] Read more.
Background/objectives: This was a post hoc analysis of safety data across the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine clinical trial development program. Methods: Data from eight clinical trials in 46,913 immunocompetent adults who received RSVpreF or placebo were analyzed. Local reactions and systemic events were assessed among non-pregnant ≥18-year-olds (n = 9517); adverse events (AEs) among pregnant and non-pregnant 18–59-year-olds (n = 9238); and vaccine-related AEs among non-pregnant ≥18-year-olds (n = 39,314). Post-marketing data in non-pregnant adults were considered. Results: Local reactions and systemic events were reported more frequently in RSVpreF versus placebo recipients; injection site pain was the most common local reaction (RSVpreF, 18.9%; placebo, 7.4%), and fatigue (23.5%; 18.4%) and headache (19.5%; 15.0%) were the most common systemic events. Percentages of AEs within 1 month after vaccination were similar across groups (RSVpreF, 12.8%; placebo, 13.1%); severe AEs were reported in ≤1.5% of participants. Differences in percentages of individuals reporting vaccine-related AEs between the RSVpreF and placebo groups were <0.2% for all related AEs. Serious AEs throughout the study were reported in ≤14.0% (RSVpreF, 12.6%; placebo, 14.0%). No atrial fibrillation, Guillain-Barré syndrome, or acute polyneuropathy cases were reported. The AE data from post-marketing data sources were consistent with the safety profile from the clinical trial program, with no new safety concerns. Conclusions: Integrated data demonstrated that RSVpreF was well tolerated with a favorable safety profile in non-pregnant and pregnant adults. Ongoing surveillance through real-world use and clinical trial experience continue to support the safety profile of RSVpreF. ClinicalTrials.gov: NCT03529773/NCT04071158/NCT04785612/NCT05035212/NCT05096208/NCT05842967/NCT04032093/NCT04424316. Full article
(This article belongs to the Special Issue Host Immunity and Vaccines for Respiratory Pathogens)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop